Stock analysts at The Goldman Sachs Group started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat reports. The brokerage set a "neutral" rating and a $24.00 price target on the stock. The Goldman Sachs Group's price target would suggest a potential upside of 3.05% from the stock's current price.
Separately, Stifel Nicolaus started coverage on Kestra Medical Technologies in a research report on Monday. They set a "buy" rating and a $28.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kestra Medical Technologies has a consensus rating of "Moderate Buy" and an average price target of $27.67.
Check Out Our Latest Stock Analysis on KMTS
Kestra Medical Technologies Stock Performance
NASDAQ:KMTS traded down $0.73 during trading hours on Monday, reaching $23.29. 62,011 shares of the stock were exchanged, compared to its average volume of 275,704. Kestra Medical Technologies has a twelve month low of $20.00 and a twelve month high of $26.06.
Kestra Medical Technologies Company Profile
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Featured Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
